CFO Maged Shenouda Buys $844K of Relmada Stock in Open Market
RLMD has more than doubled off its 52-week low of $1.44.
Summary
CFO Maged Shenouda bought 200,000 shares for $843,990 in open-market purchases on September 9-10, 2026, at $4.20-$4.25 per share, increasing his direct holdings to 1,000,000 shares.
Key Events · Ownership and Investor Activity · RLMD
-
CFO Buys $844K in Open Market
CFO Maged Shenouda acquired 200,000 shares for $843,990 in two open-market purchases on September 9-10, 2026, at prices ranging from $4.20 to $4.25 per share.
-
C-Suite Buying Cluster
This purchase follows CEO Sergio Traversa's $828,000 open-market buy disclosed the same day, totaling over $1.67 million in combined C-suite buying within 48 hours.
-
Post-Transaction Holdings
Shenouda's direct holdings increased to 1,000,000 shares following the purchases.
-
Context: CMO Departure
The purchases follow the September 8, 2026 disclosure that Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended.
Analysis · RLMD · Life Sciences
CFO Maged Shenouda bought 200,000 shares for $843,990 across two open-market purchases on September 9-10, 2026, at $4.20-$4.25 per share. This is a separate transaction from the CEO's $828,000 purchase disclosed the same day — together, the two C-suite insiders deployed over $1.67 million in open-market buying within 48 hours. The CFO's purchase represents roughly 0.19% of the company's market cap and brings his direct holdings to 1,000,000 shares. The cluster of C-suite buying follows the September 8 disclosure that the Chief Medical Officer – Urology departed, suggesting management is signaling confidence in the company's direction despite the leadership change.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLMD was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.1M. The 52-week trading range was $1.44 to $8.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.